Catalyst ligands

115754-62-6, ((1,3-Dioxolan-2-yl)methyl)tributylphosphonium bromide is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

3,5-dibromobenzaldehyde (16.1 g, 61.0 mmol) was added to a cold (ice-water bath) solution of tert-butoxide (13.0 g, 116 mmol), (l,3-dioxolan-2-ylmethyl)tri-n-butylphosphine bromide salt (4.5 M, 32 cm3, 144 mmol) in 400 cm3 of ether under argon. The mixture was stirred at 0-2 C for 2 h. 1.0 M HCl(aq) (300 cm3) was added to the mixture. The reaction was gradually warmed to room temperature and stirred at room temperature for 21 h. The two layers were separated. The aqueous layer was extracted with ether (3 x 200 cm3). The organic layer and the ether extracts were combined, washed with brine (1 x 300 cm3) and dried over anhydrous magnesium sulfate. The solvents were completely removed to leave a yellow solid. The solid was purified by column chromatography of silica gel using ethyl acetate-light petroleum (40-60 C) as eluent to give 3.36 g (19%) of A-1 as a colourless solid; deltaH(200 MHz; CDCl3) 6.68 (1 H, dd, J1A & 16 Hz, vinylH), 7.33 (1 H, d, J16 Hz, vinylH), 7.33 (2 H, m, ArH), 7.63 (1 H, m, ArH), and 9.72 (1 H, d, J7.6 Hz, CHO); m/z [CI(NH3)] 306, 308, 310 (MNH4+), and 288, 290, 292 (M+)., 115754-62-6

The synthetic route of 115754-62-6 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; ISIS INNOVATION LIMITED; THE UNIVERSITY COURT OF THE UNIVERSTIY OF ST ANDREWS; WO2004/20448; (2004); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

13104-56-8, 4′-(4-Methoxyphenyl)-2,2′:6′,2”-terpyridine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

13104-56-8, 4,4?-bipyridine (23mg, 0.15 mmol) and atpy (51 mg, 0.15 mmol) in CH2Cl2 was added to a solution of Cu(CH3COO)2¡¤H2O (30 mg, 0.15 mmol) in methanol (15 mL). After stirring for 10min, an excess of NH4PF6 (60 mg, 0.37 mmol) was added to solution. The reaction mixture was then stirred for 2 h. The solvent was removed at reduced pressure and the green residue was precipitated using diethyl ether. Yield: 32mg, 31%; m.p. 233-235 C (dec.). Anal. Calc. for C58H48Cu2F12N8O6P2¡¤1.5H2O. CH2Cl2: C, 47.72; H, 3.54; N, 7.42. Found: C, 47.26; H, 3.03; N, 7.99%. TGA-DTA: calc. by formula C58H48Cu2F12N8O6P2¡¤0.5H2O: H2O%=0.64, 2(CH3COO)%=8.44, 4,4?-bpy%=12.18, Cu(CH3COO)2%=16.18. Determined H2O%=0.71, 2(CH3COO)%=6.15, 4,4?-bpy%=12.81, Cu(CH3COO)2%=16.91. IR data (KBr, cm-1): 3389, 3055, 1598, 1470, 1407, 1243, 1189, 1019, 835, 794, 688, 641, 586, 519. Green crystals of 3 were obtained from a MeOH/diethyl ether solution.

The synthetic route of 13104-56-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Momeni, Badri Z.; Heydari, Sepideh; Polyhedron; vol. 97; (2015); p. 94 – 102;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.25316-59-0,Benzyltributylammonium bromide,as a common compound, the synthetic route is as follows.

EXAMPLE 36 3,4-Dihydro-6-(4-hydroxyphenyl)-1-methylpyrrolo[1,2-a]pyrazine (5.0 g), 100 ml of methylene chloride, 5.3 ml of benzyl bromide and 0.8 g of benzyltributylammonium bromide was added in succession to a solution of 1.8 g of sodium hydroxide in 100 ml of water under argon. The mixture was boiled under reflux overnight and stirred and subsequently cooled. After the addition of 100 ml of methylene chloride and 100 ml of water the phases were separated and the aqueous phase was extracted twice with 100 ml of methylene chloride each time. The organic phases were combined, dried with MgSO4 and freed from solvent. The residue, 10.3 g of brown oil, was chromatographed on 500 g of silica gel with methylene chloride/methanol mixtures (99:1 to 9:1) as the eluent. The crude product, 4.9 g of brown, amorphous material, was dissolved in a 10-fold amount of hot ethanol and treated with 1.1 equivalents of a saturated solution of fumaric acid in ethanol. The product, 2.2 g of yellow crystals, was recrystallized from a 20-fold amount of ethanol. There were obtained 1.8 g (19%) of 6-[p-(benzyloxy)phenyl]-3,4-dihydro-1-methylpyrrolo[1,2-a]pyrazine fumarate (1:1); m.pt.: 165-168 C. (dec.).

25316-59-0, The synthetic route of 25316-59-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Hoffmann-La Roche Inc.; US5292732; (1994); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.17217-57-1,4,4′-Dimethoxy-2,2′-bipyridine,as a common compound, the synthetic route is as follows.

4,4?-Dimethoxy-2, 2?-bipyridine (188 mg, 0.87 mmol) and sodium hexafluorophosphate (146 mg, 0.87 mmol) added to a suspension of 6 (200 mg, 0.17 mmol) in chloroform (40 mL). The mixture was refluxedat 60 ¡ãC for 48 h. The solution was concentrated to approximately 2 mLunder vacuum. Ether (20 mL) was added to the solution to give a yellow precipitate. After filtration, the crude product was purified by column chromatography (alumina gel; eluted with dicloromethane/methanol, 100:1 v/v) to give a yellow solid 3 (146 mg, 69percent). 1H NMR (400 MHz,CD3CN): delta=9.7 (d, 3JPH=20 Hz, 1 H, IrCH), 7.7?8.7 (m, 6 H, bipyridyl),7.0?7.7 (m, 30 H, PPh3), 5.2?6.4 (m, 4 H, phenyl), 4.04, 4.00 (s,6H, OCH3). 31P NMR (162 MHz, CD3CN): delta=11.5 (d, J=9.2 Hz,CPPh3), – 9.9 (s, IrPPh3). 13C NMR (101 MHz, CD3CN): delta=193.7 (s,IrCH), 167.7 (d, 2JPC=23.9 Hz, COCH3), 157.6, 157.3, 153.9, 150.9 (s,bipyridyl), 152.5 (d, 2JPC=19.4 Hz, IrCHC(PPh3)C), 146.3 (d, 2JPC=19.1 Hz, IrC), 112.1?136.1 (m, PPh3, phenyl, and bipyridyl),110.7 (d, 1JPC=90.6 Hz, IrCHC(PPh3)), 54.6, 54.3 ppm (s, OCH3). HRMS:m/z [M]+ calcd for C56H47ClIrN2O2P2+ 1069.2425, found1069.2422. IR (KBr, cm?1): 840 (P?F). Anal. Calcd for C56H47ClF6IrN2O2P3: C 55.38, H 3.90, N 2.31. Found: C 55.09, H 4.11,N 2.55percent.

17217-57-1, 17217-57-1 4,4′-Dimethoxy-2,2′-bipyridine 2733927, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Hu, Yuxuan; Dong, Yubao; Sun, Xiaona; Zuo, Guorui; Yin, Jun; Liu, Sheng Hua; Dyes and Pigments; vol. 156; (2018); p. 260 – 266;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4733-39-5,2,9-Dimethyl-4,7-diphenyl-1,10-phenanthroline,as a common compound, the synthetic route is as follows.

General procedure: 1a-j were prepared photolytically using a procedure adapted from the literature;[25] the synthesis of 1j is presented below and typifies all such syntheses performed in this work. W(CO)6(0.550 g, 1.56 mmol) was dissolved in 50mL dry tetrahydrofuran(Pharmco) and degassed in a round-bottom flask. The resulting solution was illuminated with a 100-W mercury arc lamp until nearly complete conversion to W(CO)5(THF) had been effected[26] as determined by infrared spectroscopy; this normally required 3 to 4 h of constant illumination. To the resulting yellowish-green solution was added a slight molar excess of dmp (0.347 g, 1.64 mmol) under constant stirring and nitrogen purging; this resulted in a rapid colour change and eventual precipitation of the desired product. After 30 min, the precipitate was isolated and washed with additional THF; the crude product was purified by recrystallization from dichloromethane/hexanes. The product (0.516 g, 1.02 mmol, 65%yield) consisted of brick-red crystals and its identity was confirmed by IR spectroscopy. Most of the compounds synthesized exhibited deep-red luminescence as solids.

4733-39-5, The synthetic route of 4733-39-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Bullock, John P.; Lee, Chong-Yong; Hagan, Brian; Madhani, Humair; Ulrich, John; Australian Journal of Chemistry; vol. 70; 9; (2017); p. 1006 – 1015;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

29176-55-4, 2,9-Dichloro-1,10-phenanthroline is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Stille couplingThe rigid ligand 66 was obtained by Stille bis-coupling, by condensing two residues of tributylstannylpyridazine 39 with the 2,9-dibromo-1,10-phenanthroline 65b, with a yield of 91%, whereas its dichlorinated homolog 65a enables only a more modest yield of 62% to be obtained (Scheme 31).

29176-55-4, 29176-55-4 2,9-Dichloro-1,10-phenanthroline 355196, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.); US2010/298562; (2010); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

485-71-2, Cinchonidine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,485-71-2

Resolution of the enantiomers of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-pyrazole-3-carboxylic acid The resolution of the enantiomers of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-pyrazole-3-carboxylic acid was carried out via reaction with the following chiral bases: BrucineQuinine(-)-Cinchonidine(+)-CinchonineR-(+)-1-Phenylethylamine(1 R,2S)-(-)-Ephedrine hydrochloride(1S,2R)-(+)-Ephedrine hydrochloride. In each case the reactions were carried out with 0.5 and 1 equivalents of base in respect to 1 equivalent of the acid compound and by using the following solvents EthanolAcetoneAcetonitrilDioxaneEthylacetateChloroform. The results are summarized in the following tables. It may be understood that the afore mentioned crystallisation experiments that are not reflected in the following tables did not yield crystals of the respective salts under the given conditions. However, suitable conditions for crystallization of these salts can be determined by those skilled in the art via routine experiments. In the following tables Acid represents racemic 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-pyrazo)e-3-carboxylic acid R-Acid represents the respective derivative of (R)-5-( 4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-pyrazole-3-carboxylic acid S-Acid represents the respective derivative of (S)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-pyrazole-3-carboxylic acidProcesses for crystallisation: Process A: A solution of the chiral base was added on top of a solution of the racemic acid at room temperature.Process C: A solution of the racemic acid was added on top of a solution of the chiral base. The mixture was heated to reflux and solvent was added until dissolution was complete. The solution was left to crystallisation at r.t.Process D: The chiral base was directly added on top of a solution of the racemic acid at room temperature.Process E: The chiral base was directly added on top of a solution of the racemic acid at reflux temperature.Process F: The solution of the salt was evaporated to dryness. The residue was dissolved in a minimum amount of the solvent under reflux heating. The solution was left to crystallisation at r.t.Resolution with (-)-Cinchonidine [Show Image] Acid g (mmol) Eq. amine Proc. Solvent for crystallisation T CrystYield 1st Cryst. % % S-Acid % R-Acid0,4 g (1,09 mmol) 1 F 2ml dioxane r.t 31 94,4 5,60,4 g (1,09 mmol) 1 F 19ml Ethylacetate r.t 28,5 95,8 4,20,4 g (1,09 mmol) 1 F 20ml acetone r.t. 19,6 96,9 3,10,4 g (1,09 mmol) 1 F 24ml acetonitrile r.t 42 85,8 14,1

The synthetic route of 485-71-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Laboratorios del Dr. Esteve S.A.; EP1944293; (2008); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.485-71-2,Cinchonidine,as a common compound, the synthetic route is as follows.

General procedure: A mixture of 2 or 3 (0.50 mmol), the corresponding acids RCOOH (0.60 mmol),DCC (0.60 mmol), DMAP (0.1 mmol) in dry dichloromethane (15 mL) was stirred atroom temperature. When the reaction was completed, and checked by TLC, the mixturewas filtered to remove urea from the reaction, and the filtrate was diluted bydichloromethane (45 mL). Subsequently, the diluted organic phase was washed bysaturated aqueous NaHCO3 (30 mL), and brine (30 mL), dried over anhydrousNa2SO4, concentrated in vacuo, and purified by CC to give the pure 9R/S-acyloxyderivatives of cinchonidine and cinchonine 5a-j,l-o and 6a,c,e-o [17-19]. The dataof target compounds are shown as follows.

485-71-2, The synthetic route of 485-71-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Che, Zhi-Ping; Chen, Gen-Qiang; Jiang, Jia; Lin, Xiao-Min; Liu, Sheng-Ming; Sun, Di; Tian, Yue-E; Yang, Jin-Ming; Zhang, Song; Journal of Asian Natural Products Research; (2020);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.485-71-2,Cinchonidine,as a common compound, the synthetic route is as follows.,485-71-2

General procedure: A mixture of 2 or 3 (0.50 mmol), the corresponding acids RCOOH (0.60 mmol),DCC (0.60 mmol), DMAP (0.1 mmol) in dry dichloromethane (15 mL) was stirred atroom temperature. When the reaction was completed, and checked by TLC, the mixturewas filtered to remove urea from the reaction, and the filtrate was diluted bydichloromethane (45 mL). Subsequently, the diluted organic phase was washed bysaturated aqueous NaHCO3 (30 mL), and brine (30 mL), dried over anhydrousNa2SO4, concentrated in vacuo, and purified by CC to give the pure 9R/S-acyloxyderivatives of cinchonidine and cinchonine 5a-j,l-o and 6a,c,e-o [17-19]. The dataof target compounds are shown as follows.

As the paragraph descriping shows that 485-71-2 is playing an increasingly important role.

Reference£º
Article; Che, Zhi-Ping; Chen, Gen-Qiang; Jiang, Jia; Lin, Xiao-Min; Liu, Sheng-Ming; Sun, Di; Tian, Yue-E; Yang, Jin-Ming; Zhang, Song; Journal of Asian Natural Products Research; (2020);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

3779-42-8, 3-Bromo-N,N,N-trimethylpropan-1-aminium bromide is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

COMPOUHD 48; 5-(4-Nonyloxy-phenyl)-10J5,20-tris-[4-(3-trimethylammonio- propyloxy)-phenyl] -porphyrin trichloride; Compound 45 (50 mg, 0.062 mmol) and (3-bromopropyl)- trimethylammonium bromide (162mg, 0.62 mmol, lOeqv.) are dissolved and potassium carbonate (128 mg, 0.93 mmol, 15 eqv.) is suspended under argon in absolute DMF (30 mL) and the mixture is stirred at 550C for 12 h. The solvent is removed in vacuo at 5O0C and the residue re- dissolved in a little methanol and applied to a pad of silica (2 cm deep). The unreacted ammonium salts are washed off with methanol (lOOOmL). The product is eluted with acetic acid:methanol:water (3 :2:1 by vol.). The solvents are removed under reduced pressure and the product further purified by chromatography on a column (10Og) of Sephadex LH-20 eluting with n-butanol:water:acetic acid (4:5: 1 by vol., upper phase). The solvents are removed under reduced pressure, the residue re-dissolved in a little methanol and the solution is passed through a short column of anion exchange resin (Amberlite IRC 400, chloride form) using methanol as eluent. After removal of solvent, the product is dried at high vacuum o give a violet solid. 1H-NNZ[R: deltaH (300MHz, CD3OD): 0.89 (t, 3H, 3J= 7.5 Hz). 1.18-1.34 (m, 10H)5 1.41 (bs, 2H), 1.73 (quint 2H, 3J- 7.5 Hz), 2.30-2.44 (m, 6H), 3,31 (bs, 27H)5 3.65-3.73 (m, 6H)5 3.93 (t 2H, 3J = 7.5 Hz)5 4.25-4.42 (m, 6H), 7.08 (d, 2H5 3J= 7.5 Hz)5 7.30 (d, 6H, 3J= 7.5 Hz)5 7.93 (d, 2H5 3J= 7.5 Hz)5 8.05 (d, 6H5 3J= 7.5 Hz), 8.94 (bs, 8H)

3779-42-8, The synthetic route of 3779-42-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; DESTINY PHARMA LIMITED; WO2006/765; (2006); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI